Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04001647 · ClinicalTrials.gov registry record · Early Phase 1
Targeting ER Stress in Vascular Dysfunction
A Early Phase 1 study, sponsored by Colorado State University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT04001647: Clinical Trial Early Phase 1 study, sponsored by Colorado State University.
NCT04001647 is a Early Phase 1 study that was terminated before completion, run by Colorado State University. The registered enrollment target is 17 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04001647, a Early Phase 1 study, was terminated before completion, sponsored by Colorado State University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Aging and obesity are both risk factors for cardiovascular disease (CVD). One process that links both of these conditions to CVD is vascular dysfunction. Data from animal studies indicate that endoplasmic reticulum (ER) stress may play an important role in the development of endothelial dysfunction in aging and obesity. Therefore, the goal of this study is to investigate the relative contributions of aging and obesity on vascular dysfunction and ER stress. Additionally, this study will determine if taking an oral supplement for 8 weeks will improve vascular dysfunction and ER stress. Results from this study have the potential to identify a safe treatment option for improving vascular function in aging and obese populations.
Primary Outcome
Blood flow response to increasing doses of acetycholine
Interventions
- DRUG Acetylcholine
- DRUG Sodium Nitroprusside
- DRUG Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-06-01 |
| Est. Completion | 2022-08-16 |
| Phase | Early Phase 1 |
Why NCT04001647 stopped before completion
NCT04001647 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 3 interventions - of which Acetylcholine is the first listed.
NCT04001647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04001647 about?
NCT04001647 is a clinical study titled "Targeting ER Stress in Vascular Dysfunction". Aging and obesity are both risk factors for cardiovascular disease (CVD). One process that links both of these conditions to CVD is vascular dysfunction. Data from animal studies indicate that endoplasmic reticulum (ER) stress may play an important role in the development of endothelial dysfunction ...
What is the current status of trial NCT04001647?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2019-06-01. Estimated completion is 2022-08-16.
What interventions are being tested in trial NCT04001647?
The interventions under investigation include: Acetylcholine (DRUG), Sodium Nitroprusside (DRUG), Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT04001647?
This trial is sponsored by Colorado State University, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04001647's enrollment target sits among peer trials
17 1350th of 2000 higher than 632 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI